Successful Conversion Surgery for BRCA-Mutated Pancreatic Cancer

A recent study published in Surgical Case Reports demonstrates the effectiveness of multidisciplinary treatments in a rare case of pancreatic ductal adenocarcinoma with metastasis. A 49-year-old patient diagnosed with pancreatic cancer responded positively to treatment with olaparib and modified FOLFIRINOX, achieving a pathological complete response after surgery. The patient remains recurrence-free for 2 years after the procedure, providing insights into the potential of conversion surgery in treating unresectable pancreatic cancer.

Key Takeaways:

• A 49-year-old patient with pancreatic ductal adenocarcinoma with metastasis achieved a pathological complete response after treatment with olaparib and modified FOLFIRINOX.
• The patient underwent conversion surgery after achieving disease control with platinum-based chemotherapy and maintenance therapy with olaparib.
• The successful outcome highlights the potential of multidisciplinary treatments in achieving a successful outcome in patients with unresectable pancreatic cancer.
• The case study involved treatment with olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, which has been approved as a maintenance treatment for patients with pancreatic cancer and germline mutations.
• The patient's reduced levels of tumor markers, such as the duke pancreatic monoclonal antigen type 2 and carcinoembryonic antigen, indicate a positive response to treatment.

Statistics:

• 8 courses of platinum-based chemotherapy were administered to the patient with modified FOLFIRINOX.
• 8 months of olaparib maintenance therapy were followed by chemoradiotherapy with olaparib to ensure an antitumor effect and surgical margin negativity.
• 10 months of adjuvant olaparib treatment were administered to the patient after surgery.
• 2 years after surgery, the patient remains alive without recurrence.
• The study reports of a successful outcome in a rare case of pancreatic ductal adenocarcinoma with metastasis treated with multidisciplinary treatments.

Sources:

• A Case of Successful Conversion Surgery for BRCA-Mutated Pancreatic Body-Tail Cancer with Multiple Liver Metastases Subsequent to Positive Response to Olaparib Maintenance Therapy after Modified FOLFIRINOX. Surgical Case Reports, 2025;11(1).
• NewsRx. Data on Cancer Discussed by Researchers at University of Toyama (A Case of Successful Conversion Surgery for BRCA-Mutated Pancreatic Body-Tail Cancer with Multiple Liver Metastases Subsequent to Positive Response to Olaparib Maintenance Therapy ...). Cancer Weekly. October 21, 2025; p 320.